Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Associates in Neurology
mi
from
Lexington, KY
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Associates in Neurology
mi
from
Lexington, KY
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Neuro Medical Care Associates
mi
from
Johnson City, NY
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Neuro Medical Care Associates
mi
from
Johnson City, NY
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
The Neurological Institute
mi
from
Charlotte, NC
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
The Neurological Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Hope Neurology MS Center
mi
from
Knoxville, TN
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Hope Neurology MS Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Bhupesh Dihenia, M.D., P.A.
mi
from
Lubbock, TX
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Bhupesh Dihenia, M.D., P.A.
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
EvergreenHealth
mi
from
Kirkland, WA
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
EvergreenHealth
mi
from
Kirkland, WA
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
The Polyclinic
mi
from
Seattle, WA
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
The Polyclinic
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Gomel Regional Clinical Hospital
mi
from
Gomel,
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Gomel Regional Clinical Hospital
mi
from
Gomel,
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
MDH Research LLC
mi
from
Westerville, OH
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
MDH Research LLC
mi
from
Westerville, OH
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Phoenix, AZ
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Round Rock, TX
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
San Antonio, TX
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Fort Collins, CO
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Knoxville, TN
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Lexington, KY
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Columbus, OH
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Pasadena, CA
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Aurora, CO
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Long-Term Effects of Torso-Weighting
Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study
Status: Enrolling
Updated:  12/31/1969
Samuel Merritt University, Motion Analysis Research Center
mi
from
Oakland, CA
Long-Term Effects of Torso-Weighting
Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study
Status: Enrolling
Updated: 12/31/1969
Samuel Merritt University, Motion Analysis Research Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.
Status: Enrolling
Updated:  12/31/1969
Evergreen Healthcare
mi
from
Kirkland, WA
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.
Status: Enrolling
Updated: 12/31/1969
Evergreen Healthcare
mi
from
Kirkland, WA
Click here to add this to my saved trials
Pilot Diet Study for Multiple Sclerosis
Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Pilot Diet Study for Multiple Sclerosis
Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Sutter East Bay Medical Foundation
mi
from
Berkeley, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Sutter East Bay Medical Foundation
mi
from
Berkeley, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
MS Center of California
mi
from
Newport Beach, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
MS Center of California
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
UC Davis Health System
mi
from
Sacramento, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
UC Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
UCSF Multiple Sclerosis Center
mi
from
San Francisco, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
UCSF Multiple Sclerosis Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital
mi
from
North Haven, CT
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital
mi
from
North Haven, CT
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
mi
from
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
mi
from
Baltimore, MD
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Holy Name Hospital
mi
from
Teaneck, NJ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Holy Name Hospital
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
mi
from
Albuquerque, NM
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
SUNY Buffalo - University Neurology, Inc
mi
from
Buffalo, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
SUNY Buffalo - University Neurology, Inc
mi
from
Buffalo, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials